RSS

renal cell carcinoma (RCC)

The National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending tivozanib as a first-line treatment option for advanced renal cell carcinoma (aRCC) in line with its licensed indication more

News

It has been announced by Eisai that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for the use of Kisplyx (lenvatinib) in combination with everolimus for the treatment of advanced renal cell carcinoma more

News

Interim results from the advanced renal cell carcinoma (RCC) cohort of a study evaluating Kisplyx (lenvatinib) in combination with Merck’s anti-PD-1 therapy, pembrolizumab (KEYTRUDA), have been announced by Eisai. more

News

Eisai has announced the initiation of a new trial designed to evaluate the efficacy of a combined therapy for patients suffering from advanced kidney cancer. more

Merck and Pfizer’s medication for renal cell carcinoma (RCC) is the most likely immunotherapy combination to first arrive in market, according to Global Data more

News